Kura Oncology
KURA
222 hedge funds and large institutions have $686M invested in Kura Oncology in 2026 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 70 increasing their positions, 82 reducing their positions, and 27 closing their positions.
37% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 27
3% more funds holding
Funds holding: 215 → 222 (+7)
7% more call options, than puts
Call options by funds: $2.5M | Put options by funds: $2.34M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.55% less ownership
Funds ownership: 98.13% → 95.58% (-2.5%)
15% less repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 82
23% less capital invested
Capital invested by funds: $888M → $686M (-$202M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$22.7M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$7.11M |
| 3 |
BlackRock
New York
|
+$5.38M |
| 4 |
PFCS
Pale Fire Capital SE
Prague,
Czech Republic
|
+$3.48M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$3.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$12.2M |
| 2 |
AC
Armistice Capital
New York
|
-$10.3M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
-$8.06M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$6.92M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
-$5.42M |
KURA Hedge Fund Activity: Q1 2026 in Review
222 of the 8,184 institutional investors tracked by Wall St. Rank reported a position in Kura Oncology (KURA) for Q1 2026, worth a combined $686M — down 23% from $888M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new KURA positions and 27 closed out — a net gain of 10 holders — while 70 added to existing stakes and 82 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $22.7M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $12.2M.
- 222 institutional investors held Kura Oncology (KURA) as of Q1 2026, up from 215 in Q4 2025.
- Funds reported $686M of Kura Oncology stock for Q1 2026, down 23% quarter-over-quarter.
- 37 funds opened new Kura Oncology positions in Q1 2026 and 27 closed out, a net change of +10 holders.
- The largest Kura Oncology buyer in Q1 2026 was Deep Track Capital, an estimated $22.7M added.
- The largest Kura Oncology seller in Q1 2026 was Jacobs Levy Equity Management, an estimated $12.2M sold.
Based on aggregated 13F filings for Q1 2026.